HERVolution Therapeutics

About HERVolution Therapeutics

HERVolution Therapeutics is a biotech company focused on engineering novel immunotherapies that target Human Endogenous Retroviruses (HERVs), a class of dark genome antigens, to treat aging-related diseases such as cancer, metabolic disorders, and neurodegenerative conditions. Their mission is to unlock the therapeutic potential of HERVs by empowering the immune system to address these diseases.

Products & Services

Immunotherapies Targeting HERVs:A pipeline of off-the-shelf assets designed to activate the immune system against HERVs implicated in aging-related diseases, with an initial focus on cancer, metabolic disease, and longevity.

Specialties

Immunotherapy Dark Genome Research Human Endogenous Retroviruses (HERVs) Aging-Related Diseases Cancer Treatment Metabolic Disease Treatment Neurodegenerative Disease Treatment Protein Engineering Immunology Virology Oncology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 11700000 MR: - FA: 11.7 million FAN: 11700000	D: 2024-12-19 FD: 2024-12-19	2 investors

Series A Latest

2024-12-19

$11.7M

2 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

T

Tine Gaziel

Chief Medical Officer

A

Anne-Marie Andersson

Chief Technology Officer

J

Jan Villadsen

Chief Financial Officer

P

Peter Holst

Chief Scientific Officer

J

J. Robert Coleman

Chief Executive Officer

View 2 more team members with Pro

Unlock Full Team Directory

Recent News